CHM-The only ASX listed CAR-T comp with 2/3 human trials, page-7

ALA is a bit of an anomaly in this market. Back in its SUD days it was unloved and in the slumps. But now it has the market interest and has people willing to buy.
CHM is plodding along doing exactly what it said it would do. It has drug hitting arms in disease with unmet needs. It is attacking solid tumours with Tcells and attacking blood cancer with NK cells. Not many peers achieving this.
The market cap does not represent where the company is at. This happens. Lets see what happens at the end of year when we get some updates. A longer span view than daily share price is needed.
Lots of room to move north, share price wise, before approaching fair value. So it still presents good value for those that can wait. There is a lot of room for the share price to move, so buyers will be happy waiting and taking cheap shares when offered. A lower risk move is to wait for a proven price move up before investing. So cant see much happening until some kick @rse news gets the party started.

For now we wait.